NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

About this update from Newamsterdam Pharma Company N.v.

NAARDEN, the Netherlands and MIAMI , May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences: William Blair 45 th Annual Growth Stock Conference in Chicago, IL on Tuesday, June 3, 2025 . Michael Davidson , M.D., Chief Executive Officer, will present a corporate overview at 3:20 p.m. CT on Tuesday, June 3 . Jefferies Global Healthcare Conference 2025 in New York, NY on Wednesday, June 4, 2025 . Ian Somaiya , Chief Financial Officer, will participate in a fireside chat at 10:30 a.m. ET on Wednesday, June 4 . Goldman Sachs 46 th Annual Healthcare Conference in Miami, FL on Monday, June 9, 2025 . Michael Davidson , M.D., Chief Executive Officer, and Matthew Phillipe , Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 2:40 p.m. ET on Monday, June 9 . Live webcasts of these presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com . Following the live webcasts, archived replays will be available on the Company’s website. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Matthew Philippe P: 1-917-882-7512 [email protected] Media Contact Spectrum Science on behalf of NewAmsterdam Jaryd Leady P: 1-856-803-7855 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected] Source: NewAmsterdam Pharma N.V.

View stock analysis, news, and events for Newamsterdam Pharma Company N.v.